Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
Prestige Consumer Healthcare Inc. markets, sells, manufactures and distributes over-the-counter consumer healthcare products to retail outlets in the U.S. and Canada, Australia and other international markets. Its brand portfolio spans women’s health, pain relief, eye care, oral care, motion sickness, gastrointestinal, pediatric, lice treatment, ear care, rehydration, and nasal and sinus care, including Monistat, Summer’s Eve, Clear Eyes, TheraTears, DenTek, Dramamine, Fleet, Chloraseptic, Compound W, Little Remedies, Nix, Debrox, Hydralyte and Fess.
Company news commonly covers fiscal earnings releases, investor presentations, brand and category performance, supply conditions for key products such as Clear Eyes, share repurchase activity, capital-structure updates, material agreements and completed portfolio actions such as the Pillar5 Pharma eye care supplier acquisition.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Prestige Consumer Healthcare Inc. (NYSE:PBH) is set to release its fiscal 2023 fourth quarter and year-end earnings on May 4, 2023, before market opening. The company will hold a conference call on the same day at 8:30 a.m. ET to discuss these results. Investors can access the live webcast through the company's Investor Relations page or register for a phone call. A replay of the call will be available for a week post-event. Prestige Consumer Healthcare offers a diverse range of consumer healthcare products including Monistat®, BC®, Dramamine®, and many others, serving markets across the U.S., Canada, Australia, and beyond.
Prestige Consumer Healthcare (PBH) reported Q3 fiscal 2023 revenues of $275.5 million, a 0.4% increase from the previous year, with 1.8% growth excluding currency effects. Net income rose to $52.0 million, yielding diluted EPS of $1.04, up 5.1%. For the first nine months, revenues reached $841.9 million, a 2.7% increase year-over-year. The International OTC segment saw record revenues, growing 15.0% to $38.6 million. Management anticipates fiscal 2023 revenues between $1,120 and $1,122 million, projecting over 3% growth.